Company Overview
About Cencora
Cencora, Inc. (formerly AmerisourceBergen, rebranded August 2023) is a Conshohocken, Pennsylvania-based pharmaceutical distribution and healthcare services company — publicly traded on the New York Stock Exchange (NYSE: COR) as an S&P 500 Health Care component, ranked #10 on the 2024 Fortune 500 and #24 on the Global Fortune 500 — distributing brand-name, generic, and specialty pharmaceuticals, over-the-counter products, and home healthcare supplies to 110,000+ points of care across 11 countries through 46,000+ employees and $316+ billion in annual revenue. Cencora operates as one of the "Big Three" pharmaceutical wholesalers in the United States alongside McKesson and Cardinal Health, collectively supplying approximately 90%+ of the US pharmaceutical supply chain. The company distributes from 26 US pharmaceutical distribution centers and 1,300+ locations across 50+ countries. In January 2025, Cencora completed the acquisition of approximately 85% interest in Retina Consultants of America (RCA) — a leading management services organization for retina specialists — for $4.4 billion, advancing its strategy to expand from pharmaceutical distribution into specialty physician-administered treatments and the high-growth specialty pharmaceutical services market. Founded through the 2001 merger of AmeriSource Health Corporation and Bergen Brunswig Corporation, with predecessor companies tracing to the 1970s, Cencora adopted its current name (meaning "center, core, heart" in multiple languages) in 2023 to signal the brand's evolution beyond commodity distribution.
Business Model & Competitive Advantage
Cencora's pharmaceutical distribution model addresses the supply chain complexity that drug manufacturers, hospital systems, independent pharmacies, and specialty clinics face when sourcing medications across 80,000+ NDC codes (National Drug Codes): a regional health system purchasing oncology drugs (branded biologics at $50,000-500,000 per patient per year), specialty injectables, controlled substances, and generic high-volume medications from hundreds of manufacturers would require hundreds of direct manufacturer relationships, credit facilities, cold chain logistics networks, and DEA scheduling compliance programs without a pharmaceutical wholesaler aggregating these relationships into a single distribution relationship. Cencora's scale ($316B+ revenue) enables manufacturer rebate negotiations (collecting prompt-payment discounts and distribution service agreements from manufacturers that are passed to pharmacy customers), inventory float economics (holding pharmaceutical inventory that is resold within days, generating returns on float), and specialty logistics (temperature-controlled shipping, patient assistance program management, REMS compliance) that independent pharmacies and physician practices cannot self-provide.
Competitive Landscape 2025–2026
In 2025, Cencora competes in the US pharmaceutical distribution and specialty healthcare services market with McKesson Corporation (NYSE: MCK, #1 US pharma distributor, $360B+ revenue), Cardinal Health (NYSE: CAH, #3 US pharma distributor, $225B revenue), and specialty pharmacy and services companies (Diplomat Specialty, PharMerica) for pharmaceutical distribution contracts with hospital systems, retail pharmacy chains, and independent pharmacies. The Retina Consultants of America acquisition ($4.4B, January 2025) represents Cencora's most significant move beyond distribution into the specialty physician practice management model — acquiring MSO infrastructure that serves retina specialists who administer anti-VEGF injections (Eylea, Lucentis, Vabysmo) that are among the highest-revenue physician-administered drugs in ophthalmology. The 2025 strategy focuses on integrating RCA into the specialty care platform, growing the specialty logistics and commercialization services for biopharma manufacturers, and defending distribution contract renewals against McKesson in the independent and regional chain pharmacy segments.
The Cencora Story
Founders
Company Timeline
Major milestones in Cencora's journey
Leadership Team
Meet the leaders behind Cencora
Robert P. Mauch
Dr. Robert 'Bob' Mauch became President and CEO of Cencora in October 2024, making him the third CEO in the company's 23-year history. He holds a PharmD degree from Mercer University (1991) and a PhD in Pharmacy Administration from the University of South Carolina (1994). Dr. Mauch founded Xcenda, LLC in 1994, which provided health economics and strategic consulting to pharmaceutical companies. He joined Cencora in 2007 when the company acquired Xcenda and has since led the company's transformation into a united global provider of pharmaceutical-centered healthcare solutions, driving focus on customer experience, innovation, and digital transformation.
Steven H. Collis
Steven H. Collis served as Chairman, President, and CEO of Cencora until October 2024, when he transitioned to Executive Chairman. Born in South Africa, he earned a Bachelor of Commerce from the University of Witwatersrand. Steve joined AmerisourceBergen in 2001 and became CEO in July 2011. Under his leadership, annual revenue tripled from $80 billion to over $250 billion, and the company expanded globally to serve more than 46,000 team members across 50+ countries. He helped found the Specialty Group business in 1994 and led strategic acquisitions including World Courier (2012) and MWI Veterinary Supply (2015).
James F. Cleary
Jim Cleary is EVP and CFO, responsible for managing Cencora's financial strategy including accounting, corporate finance, investor relations, treasury, tax, audit, and shared business services. He joined Cencora in 2015 when the company acquired MWI Veterinary Supply, where he served as CEO. Prior to being named CFO in 2018, he was Group President of Global Commercialization Services and Animal Health. He holds a Bachelor of Arts in Economics from Dartmouth College (1985) and an MBA from Harvard Business School (1990). He has over 20 years of industry experience, including serving as President of MWI Veterinary Supply from 1997 to 2017.
Francois Mandeville
Francois Mandeville was appointed EVP of Strategy and M&A in November 2024. He leads Cencora's strategic planning initiatives and merger and acquisition activities, playing a key role in identifying growth opportunities and executing strategic transactions that advance the company's mission to improve global healthcare.
Pawan Verma
Pawan Verma was appointed EVP and Chief Data and Information Officer in November 2024. He oversees Cencora's data strategy, information technology infrastructure, and digital transformation initiatives, ensuring the company leverages advanced technology and data analytics to optimize healthcare delivery and business operations.
Juan Guerra
Juan Guerra leads Cencora's International Business Group, overseeing operations across more than 50 countries. He is responsible for the company's global expansion strategy and manages the integration of international acquisitions, including the significant Alliance Healthcare business acquired in 2021 that expanded Cencora's presence across 11 European countries.
Open Positions
Reddit Discussions
Key Differentiators
Market Leader
Cencora is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $316000M in revenue, Cencora operates at enterprise scale with proven market validation.
Frequently Asked Questions
Not So Random Others
YouShift
YouShift is a United States-based AI healthcare workforce management platform — building the operating system for healthcare staffing starting with AI-powered scheduling agents that replace the comple
Hermes Robotics
Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and ma
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Bucket Robotics
Bucket Robotics is an autonomous mobile robot (AMR) company that designs modular, rapidly deployable robots for warehouse automation and industrial material handling. Unlike traditional warehouse auto
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
Dusty Robotics
Dusty Robotics is a Mountain View, California-based construction robotics company — backed with $69.5 million in total funding from Root Ventures, Scale Venture Partners, Canaan Partners, GRIDS Capita
Compare Cencora with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Cencora? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Cencora Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Cencora vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →